News Center
COLUMN NAME
Search
Yinfeng in Chinese
Yinfeng in Chinese
Content details
Mesenchymal stem cell transplantation in the treatment of refractory systemic lupus erythematosus
Date:2016-06-19 14:31:27 Author:管理员 Browse:1615次

In recent years, some scholars have put forward "autoimmune disease is a hematopoietic stem cell disease" theory, and that stem cell abnormalities is the primary defect, but other scholars believe that the secondary defects. 1996 Italy scholar Marmont first reported with autologous bone marrow transplantation for the treatment of severe lupus erythematosus (lupus erythematosus) success. Thereafter, at home and abroad quickly launched a autologous peripheral blood stem cell transplantation and autologous bone marrow transplantation for treatment of severe lupus has obtained the good curative effect. Hematopoietic stem cell transplantation can make some patients to achieve the disease control, antibody titers decreased, the disease is in long-term remission. But the cost is high, the complication and the recurrence rate is as high as 40% ~ 50%, which can not be used routinely. In recent years, the study of bone marrow mesenchymal stem cells, it is found that there are many kinds of immune regulation effect of bone marrow mesenchymal stem cells. It can not only support hematopoiesis, but also restrain the generation of antibodies and repair the damaged tissue. Recent studies have found that there are abnormal bone marrow mesenchymal stem cells in patients with systemic lupus erythematosus. Therefore, the theory of "systemic lupus erythematosus is a bone marrow mesenchymal stem cell disease" is put forward. Therefore, allogeneic bone marrow mesenchymal stem cell transplantation can be used in the treatment of systemic lupus erythematosus.


The treatment of severe lupus erythematosus with bone marrow and umbilical cord mesenchymal stem cells transplantation in Department of rheumatism in Nanjing Gulou Hospital in 2007 has been achieved good effect, so far more than 40 cases have been completed. Umbilical cord derived mesenchymal stem cells for the treatment of patients with severe lupus erythematosus, the efficacy of positive, no adverse reactions. Long term follow-up of many patients without relapse or long-term remission. At present, the research on the transplantation of mesenchymal stem cells in the treatment of autoimmune disease is in the international advanced level.


A piece of cord is equal to 5000ML bone marrow contains mesenchymal stem cells, and umbilical cord mesenchymal stem cells more pure, easy collection, high activity, can amplified many times use, does not need to match the type, can be used in the family, closer genetic relationship of effect will be better! The world's largest clinical trial registration website clinicaltrials.gov "statistical results show that through the end of January 2016, domestic and foreign registered mesenchymal stem cell clinical trial, a total of 557, applications include cardiovascular and cerebrovascular diseases, autoimmune diseases, metabolic diseases, liver disease.